Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: A multicentre, placebo-controlled, dose-comparison study

British Journal of Rheumatology

Volumn 37, Issue 9, 1998, Pages 952-960

  Black, C M ^f   Halkier Sorensen L ^a   Belch, J J F ^f   Ullman, S ^b   Madhok, R ^f   Smit, A J ^c   Banga, J D ^d   Watson, H R ^e  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e BAYER PHARMA AG   (Germany)

^f NONE

Author keywords

Iloprost; Optimal dose; Raynaud's phenomenon; Systemic sclerosis

Indexed keywords

ILOPROST; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUSHING; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS; TRISMUS;

EID: 0031663570     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/37.9.952     Document Type: Article

References (24)

1. Belch JJF. Raynaud's phenomenon. Curr Opin Rheumatol 1989;1:490-8.
2. Campell PM, Le Roy EC. Pathogenesis of systemic sclerosis: A vascular hypothesis. Semin Arthritis Rheum 1975;4:351-68.
3. Kahaleh MB. Vascular disease in scleroderma: Endothelial cell injury hypothesis. Rheum Dis Clin N Am 1990;16:57.
4. Saniabadi AR, Lowe GDO, Belch JJF, Forbes CD, Prentice CRM, Barbenel JC. The novel effect of a new prostaglandin analogue ZK36-374 on the aggregation of human platelets in whole blood. Thromb Haemostasis 1983;50:718-21.
5. Kahaleh MB, Osborn I, LeRoy EC. Elevated levels of circulating platelet aggregates and beta-thromboglobolin in scleroderma. Ann Intern Med 1982;96:910-3.
6. 2) receptor. Arthritis Rheum 1984; 27:139-46.
7. Zamora MR, O'Brien RF, Rutherford RB, Weil JV. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon. Lancet 1990;336: 1144-7.
8. Bunker CB, Terenghi G, Springall DR et al. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon. Lancet 1990;336:1530-3.
9. Rustin MHA, Bull HA, Machin SJ et al. Serum from patients with Raynaud's phenomenon inhibits prostaglandin release. J Invest Dermatol 1987;89:555-9.
10. Holt CM, Moult J, Lindsey N, Hughes P, Greaves M, Rowell NR. Prostacyclin production by human umbilical vein endothelium in response to serum from patients with systemic sclerosis. Br J Rheumatol 1989;28:216-20.
11. Lau CS, O'Dowd A, Belch JJF. White cell activation in the Raynaud's phenomenon of systemic sclerosis and vibration induced white finger syndrome. Ann Rheum Dis 1992;51:249-52.
12. Bruckdorfer KR, Hillary JB, Bunce T, Vancheeswaran R, Black CM. Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum 1995;38:1060-7.
13. Prescott RJ, Freemont AJ, Jones CH, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992;166:255-63.
14. Krause W, Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol 1985;30:61-8.
15. Müller B, Witt W, McDonald FM. Iloprost: stable prostacyclin analogue. In: Rubanyi GM, ed. Cardiovascular significance of endothelium-derived vasoactive factors. Mount Kisco, NY: Futura Publishing Co., Inc., 1991.
16. Yardumian DA, Isenberg DA, Rustin M et al. Successful treatment of Raynaud's syndrome with iloprost, a chemically stable prostacyclin analogue. Br J Rheumatol 1988;27:220-6.
17. McHugh NJ, Csuka M, Watson HR et al. Infusion of iloprost, a prostacyclin analogue, for the treatment of Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 1988;47:43-7.
18. Rademaker M, Cooke ED, Almond NE et al. Comparison of intravenous infusions of iloprost and nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. Br Med J 1989;298:561-4.
19. Torley HI, Madhok R, Capell HA et al. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis 1991;50:800-4.
20. Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischaemic ulcers secondary to systemic sclerosis. J Rheumatol 1992;19:1407-14.
21. Belch JJF, Capell HA, Cooke ED et al. Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study. Ann Rheum Dis 1995;54:197-200.
22. Masi AT, Rodnan GP, Medsger TA et al. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
23. Wollersheim H, van Zwieten PA. Treatment of Raynaud's phenomenon. Eur Heart J 1993;14:147-9.
24. Wigley FM, Wise RA, Seibold JR et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. Ann Intern Med 1994;120:199-206.